Post navigation Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell LymphomaServices PMI® at 56.1%; February 2026 ISM® Services PMI® Report